This prospective outcome study is designed to assess the safety of rivaroxaban in the pre-diagnosis phase of DVT.~International guidelines suggest the use of low molecular weight heparin (LMWH) if the diagnostic process is expected to be delayed for more than 4 hours.~Rivaroxaban is a new DOAC that in clinical trials has proven to be non-inferior to LMWH and warfarin for the treatment of DVT with the added benefit of causing less major bleeding.~Because of its rapid onset of action and oral administration, rivaroxaban could be used instead of LMWH in the pre-diagnosis phase pending the results of the diagnostic test. However, the safety of a such proposed indication has to be proven before it can be adopted in clinical practice.~This study aims to determine the safety and feasibility of pre-diagnostic treatment with rivaroxaban. The primary outcome of this study safety is a composite endpoint of serious bleedings encountered within 48 hours after administration of rivaroxaban.
This prospective outcome study is designed to assess the safety of rivaroxaban in the pre-diagnosis phase of DVT.